(Q39809616)

14 September 2017

title

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide (English)

1 reference

14 September 2017

1 reference

Marie-Claude Beauchamp

1

1 reference

14 September 2017

Ariane Knafo

2

1 reference

14 September 2017

Amber Yasmeen

3

1 reference

14 September 2017

Joan M Carboni

4

1 reference

14 September 2017

Marco M Gottardis

5

1 reference

14 September 2017

Michael N Pollak

6

1 reference

14 September 2017

Walter H Gotlieb

7

1 reference

14 September 2017

language of work or name

English

0 references

publication date

21 August 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

115

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

193-198

1 reference

14 September 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Diagnostic markers for early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

IGF-I in epithelial ovarian cancer and its role in disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

The insulin-like growth factor 1 receptor in cancer: old focus, new future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

The insulin-like growth factor insulin system in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Insulin-like growth factor receptor I targeting in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Mitochondria and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Resistance to therapy caused by intragenic deletion in BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Characterization of four novel epithelial ovarian cancer cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

The comet assay: a method to measure DNA damage in individual cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

DNA damage response and apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Ovarian cancer: a focus on management of recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

The potential of PARP inhibitors in genetic breast and ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Development of PARP inhibitors in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Negative Regulation of AKT Activation by BRCA1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.009

10.1016/J.YGYNO.2009.07.009

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference